Asterand Bioscience, a global leader in human tissue-based research tools and solutions for drug discovery, was formed in 2006 through the merger of Asterand and Pharmagene. It offers top-quality, well-characterized human tissue and research solutions to accelerate drug target identification and validation. With a deep-rooted expertise in human tissue, the company leverages its capabilities in human tissue procurement, characterization, and research tools to address the research needs of pharmaceutical, biotechnology, and diagnostic companies, as well as academic institutions.
The company, operating from offices in Detroit, MI, and Royston, U.K., received a $3.00M Series C investment on 26 November 2003, from Arboretum Ventures, Chrysalis Ventures, Apjohn Ventures, Oxford Bioscience Partners, Fort Washington Investment Advisors, Inc. This investment reflects the confidence of prominent venture capital firms in Asterand's mission to elevate drug discovery and accelerate the path to clinical success.
Asterand Bioscience, founded in 2000, operates in the Biotechnology, Health Care, and Life Sciences industries, demonstrating a strong track record and ongoing commitment to advancing human tissue-based research in the pharmaceutical and biotechnology sectors.
